Saxenda of Novonodisc, a drug that can be used in children and adolescents, has emerged as an option for the first time. Effective weight loss is expected to help treat obesity in children and adolescents, but the fact that there is little data on Koreans should be supplemented.

Novonodisc held a " Saxenda expansion of Pediatric Adaptation Meeting" at the Shilla Hotel in Jung-gu, Seoul on the 10th and pointed out the meaning of treating obesity in children and adolescents.

Saxenda (Liraglutide), a GLP-1 analog, obtained an indication for pediatric and adolescent administration from the MFDS in December last year. The targets are children and adolescents aged 12 or older who are obese wit